DICE Therapeutics, Inc.

Eli Lilly is relatively young in immunology, but it has demonstrated a strategic commitment to growing its pipeline and presence in rheumatologic, dermatologic and gastroenterologic indications. Its f

Bain Capital Life Sciences (BCLS) raised its largest investment fund yet, nearly doubling the amount of money it has at its disposal to back both private and public drug developers, medical device and

Already a major player in integrin therapy for diabetes and obesity with Mounjaro/Zepbound (tirzepatide), Eli Lilly and Company now is looking to that drug class to add critical mass in gastrointest

The road to starting up and funding a new biopharmaceutical venture is paved with plenty of speedbumps, but certain big pharma companies and investors have made efforts to smooth the path for start-up